Ongoing clinical trials of ErbB-targeted therapy in UC
Drugs | Targets | Combination | Conditions | Phase | NCT |
---|---|---|---|---|---|
Afatinib | ErbB-1/2 (EGFR/ HER2) | Null | Adv UC | II | NCT02122172 |
Afatinib | ErbB-1/2 (EGFR/ HER2) | Null | Adv solid tumors | II | NCT02465060 |
Cetuximab | ErbB-1 (EGFR) | TTX-080 | Cancer | I | NCT04485013 |
Cetuximab | ErbB-1 (EGFR) | SNK01 | UC | I/II | NCT04464967 |
Lapatinib | ErbB-1/2 (EGFR/ HER2) | Null | UC | II/III | NCT00949455 |
Lapatinib | ErbB-1/2 (EGFR/ HER2) | Paclitaxel | UC | II | NCT01700010 |
Trastuzumab deruxtecan | ErbB-2 (HER2) | Null | UC | II | NCT04482309 |
Trastuzumab deruxtecan | ErbB-2 (HER2) | Nivolumab | UC | I | NCT03523572 |
Trastuzumab deruxtecan | ErbB-2 (HER2) | Pyrotinib | Met/Adv UC, HER2 positive | II | NCT05318339 |
Trastuzumab deruxtecan | ErbB-2 (HER2) | Tucatinib | Urologic neoplasms | II | NCT04579380 |
Trastuzumab deruxtecan | ErbB-2 (HER2) | AZD5305 | UC | I/II | NCT04644068 |
RC48-ADC | ErbB-2 (HER2) | Null | UC | NMIBC | II | NCT05996952 |
RC48-ADC | ErbB-2 (HER2) | Toripalimab | UC | MIBC | II | NCT05297552 |
RC48-ADC | ErbB-2 (HER2) | Triplizumab | UC | MIBC, HER2 positive | II | NCT05356351 |
RC48-ADC | ErbB-2 (HER2) | Triplizumab | UC | II | NCT05016973 |
RC48-ADC | ErbB-2 (HER2) | Toripalimab | UC | MIBC, HER2 positive | II | NCT05979740 |
RC48-ADC | ErbB-2 (HER2) | pembrolizumab | UC | II | NCT04879329 |
RC48-ADC | ErbB-2 (HER2) | pembrolizumab | UC | III | NCT05911295 |
Trastuzumab emtansine | ErbB-2 (HER2) | Null | UC | II | NCT02675829 |
Null in combination indicates that the trial is monotherapy. ErbB: erythroblastic oncogene B; EGFR: epidermal growth factor receptor; HER2: human epidermal growth factor receptor 2; MIBC: muscle-invasive bladder cancer; NMIBC: non-MIBC; UC: urothelial carcinoma; Adv: advanced, Met: metastatic, Rec: recurrent; RC48-ADC: disitamab vedotin; NCT: national clinical trial
SS, LZ, and KL contributed equally to: Writing—original draft, Writing—review & editing. ML, JZ, DJ, DW, ZS, and PX: Investigation, Writing—review & editing. JY and ZZ: Conceptualization, Writing—review & editing, Supervision. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
This study was supported by the Shaanxi Province Key Industry Chain Project [2022ZDLSF05-14]. The funder played no role in the study design, data collection and analysis, decision to publish, or in the preparation of the manuscript.
© The Author(s) 2024.